The epidemic of atherosclerotic cardiovascular disease in India

J Clin Lipidol. 2020 Mar-Apr;14(2):170-172. doi: 10.1016/j.jacl.2020.01.010. Epub 2020 Jan 30.

Authors

P Barton Duell¹, Vimal Mehta², Devaki Nair³, Sonika Puri⁴, Rashmi Nanda⁵, Raman Puri⁶

Affiliations

¹ Knight Cardiovascular Institute and Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA. Electronic address: duellb@ohsu.edu.
² G. B. Pant Institute of Postgraduate Medical Education and Research, New Delhi, India.
³ Lipids and CVD Prevention, Royal Free NHS Foundation Trust Hospital, London, UK.
⁴ Department of Nephrology/Transplant, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
⁵ Cardiac Care Centre, New Delhi, India.
⁶ Indraprastha Apollo Hospitals, New Delhi, India.

PMID: 32094008
DOI: 10.1016/j.jacl.2020.01.010

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal
Cardiovascular Diseases*
Cholesterol, LDL
Consensus
Goals
Humans
Hyperlipoproteinemia Type II*
India
Proprotein Convertase 9
Secondary Prevention

Substances

Antibodies, Monoclonal
Cholesterol, LDL
PCSK9 protein, human
Proprotein Convertase 9